Linked Life Data

9835865

Source:http://linkedlifedata.com/resource/pubmed/id/9835865

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
1998-12-7
pubmed:abstractText
40% of testicular tumours are seminomatous tumours. The low mass tumours (LMT) (stages IIA and IIB of the Royal Mardsen Hospital classification) are usually treated by radiotherapy and the high mass tumours (HMT) (stage IIC, III and IV) by chemotherapy. Chemotherapy regimens are platinum-based polychemotherapy. We report 9 cases of seminomatous testicular tumours (4 LMT and 5 HMT) treated by chemotherapy (BEP modified or CBDCA-etoposide regimens), three courses, with one supplement course if necessary and surgery if residual masses are more than 3 cm long. The rate of complete remission are 100% for LMT and 60% for HMT. This could be an indication to treat in addition with orchidectomy the LMT with chemotherapy and not with radiotherapy (standard-gold) which is more toxic.
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0007-4551
pubmed:author
pubmed:issnType
Print
pubmed:volume
85
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
887-91
pubmed:dateRevised
2009-11-11
pubmed:meshHeading
pubmed:year
1998
pubmed:articleTitle
[Metastatic pure seminomas of the testicle: role of chemotherapy].
pubmed:affiliation
Service de radiothérapie-oncologie médicale, Hôpital d'Instruction des Armées du Val-de-Grâce, Paris.
pubmed:publicationType
Journal Article, English Abstract, Review